FY20 results reflect a year of trading in-line with earlier expectations, until being significantly interrupted in Q4/20 by the impact of Covid-19. Despite this, 1pm remained profitable throughout, despite accepting forbearance requests and prudently lifting bad debt provisions for the future. Post-period, there has been a noticeable pick-up in trading as the UK economy recovers, which 1pm is currently positioning itself for. A P/TNAV of 0.55x materially undervalues 1pm, hence we remain at “Buy”.
Companies: 1pm Plc
A robust set of FY20E numbers and the absence of evidence of material bad debts increases, should reassure today and provide evidence 1pm's multi-product, sector diverse, hybrid model can deliver in tougher conditions. Given a NAV p/s of 62p (30p tangible), which now includes enhanced Covid-19 provisions, the material discount to book is clearly unwarranted.
1pm has been approved for accreditation as a lending partner under the UK Government's Coronavirus Business Interruption Loan Scheme (CBILS). CBILS should provide a boost to new originations, which have come under pressure as COVID-19 impacts those sectors deemed non-critical. Levels of forbearance remain in-line with market peers and appear low versus a valuation factoring in material impairment to NAV.
1pm has provided a trading update outlining its response to the current Covid-19 outbreak. Operations continue as usual (remotely) and the group continues to write new business, however, it has received multiple requests for repayment deferrals. The group is offering this flexibility where merited to assist credit worthy UK SMEs and has the balance sheet to absorb these lower cash collections. 1pm's own funders remain supportive to the business. Given the uncertainty over the duration of the outbreak and the impact the UK's shutdown is having on 1pm's trading, we withdraw forecasts and put our recommendation under review.
Inspecs, a UK designer, manufacturer and distributor of eyewear frames to global retail chains announces its intention to IPO onto AIM raising £94m with a market cap of £138m. Admission expected 27th February. FY Dec 2018 numbers show revenue of $57m and underlying EBITDA of $11m
Companies: SO4 TRP ECHO OPM EBQ SBTX CGH PTRO PEN
1pm's interim results are robust but slightly weaker than expected with revenues of £15.6m (-2% YoY) and adj EBIT of £3.2m (-21%). Originations growth remained healthy through difficult macro conditions, with the hybrid model allowing 1pm to generate income without taking on unnecessary risk. Consequently, in combination with the costs in running a long-term sustainable business, 1pm is encountering some profit headwinds. We have updated our forecasts accordingly. The shares remain materially undervalued on most metrics.
1pm's FY19A results were well flagged by June's trading update with revenues of £31.8m (+6% YoY), adj PBT of £8.1m (+4%), while adj EPS grew +2%. Growth this year has come from purely organic means. FY20E will be somewhat of an investment year, building out management and infrastructure to accelerate revenues strongly over FY21-22E. 1pm is focused on sustainable lending over chasing volumes at lower margins.
SEC S.p.A. Adm ission is follow ing a reverse takeover under Rule 14 by SEC S.p.A of Porta Com m unications plc, another AIM quoted company. No funds being raised. Due 4 September. Mkt cap c £9.9m. The merger will create a business with global fee income of around €80m and a host of PR agencies, including Newgate, Publicasity and Newington.
Companies: OPM STKR MATD RENX JSG SOLI QIL ECHO LVCG CHRT
Warren Buffett once said that as an investor, it is wise to be ‘fearful when others are greedy and greedy when others are fearful’. Fear is not in short supply right now.
Companies: OPM ALU ANCR BLV CONN CRC STU GATC HAT LEK MMH MCB MWE NXR NTBR NOG PAF PEG RFX SRC TEF TEG TPT VTU WYN XLM
1pm's pre-close confirms a positive FY19E outcome in-line with forecasts, with revenues of £31.8m (+6% YoY) and adj PBT of £8.2m (+4%). In line with the Group's new strategic plan to grow the loan book to £350m (currently £134m), investment in sales and supporting infrastructure will be made during FY20E to accelerate growth in FY21E and beyond. We therefore now expect profit growth to be restricted in FY20E, reflecting this investment, before organic growth accelerates, such that we expect revenues to surpass £40m by FY22E, with EPS climbing to 8.3p p/s.
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Alumasc Group plc, the prem ium building products, system s and solutions group, has announced its intention to m ove from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
Companies: FOX RBD AGL CBP ADV OPM LTG K3C KAV AA/
How small- and mid-cap quoted companies make a substantial contribution to markets, employment and tax revenues.
Companies: OPM AVO AJB ARBB CMH CLIG DPP FLTA GTLY GDR HAYD KOOV LWRF MCL MUR OXB PCA PHP RE/ STX SIXH TRX TON VTA W7L
Although the focus of Hardman & Co is predominantly on companies in the smallto mid-sized market capitalisation range, when writing research reports, it is important to position them relative to the industry in which they operate. Apart from Japanese companies, all the major global pharmaceutical companies have reported full-year results for 2018 over the past few weeks; therefore, we have taken the opportunity to update our industry database and generate the first cut of global rankings for 2018. For an industry that requires a long investment cycle – it still takes, on average, 10 years from discovery to launch of a new drug – decisions made many years ago have important consequences on current financial results. Therefore, looking back at operational performance over 20 years reveals how different company strategies have panned out.
Companies: OPM AVO AJB AGY ARBB CMH CLIG CSH DNL GTLY HAYD KOOV LWRF MCL MUR NSF OXB PCA PHP RE/ REDX STX SCE SIXH TON VAL VTA W7L
Research Tree provides access to ongoing research coverage, media content and regulatory news on 1pm Plc.
We currently have 65 research reports from 6
Full-year results to 31 May 2020 deliver revenue of £15.0m (+10.3%) and EBITDA of £6.8m (+36.0%) as noted at the acquisition of Quantuma Advisory. We continue to believe a key value driver of owning K3 shares is an investor’s exposure to the positive disruption being wrought by the company’s model, which now has the ability to be applied to synergistic markets across the addressable professional services SME sector as a result of the two recent acquisitions. The already proven restructuring and insolvency practice specifically has the potential to deliver significant upside in the current environment. We reiterate our estimates, noting EPS growth of 63% between 2020A and 2023E. Target price remains 300p, offering 100% upside from the placing price of 150p.
Companies: K3 Capital Group Plc
H120 adjusted EBITDA of £9.1m was the main positive surprise for us in Ergomed’s full interim report released today. We have increased our adjusted EBITDA forecasts to £18.3m (up 8.6%) in 2020 and £20.1m (up 6.8%) in 2021. A strong order book (£151.4m, up 22.0% from the end of 2019) with high visibility into 2021, continued overall business growth and a strong balance sheet should allow Ergomed to successfully navigate the COVID-19 pandemic, invest in organic growth and look for potential strategic acquisitions. Our valuation is upgraded to £409m or 845p/share.
Companies: Ergomed Plc
Positive EBITDA in FY20A was a major milestone. Investment across the business is up and there is a clear strategy in place to deliver value for shareholders. The balance sheet is strong post the placing and the business is now self-sustaining. In light of this Rosslyn trades on an unwarranted discount to the software sector.
Companies: Rosslyn Data Technologies Plc
Keywords Studios has again showed the resilience of its model in H120, delivering 8% l-f-l revenue growth, 19% adjusted EBITDA growth and 17% adjusted EPS growth despite the impact of COVID-19. Adjusted EBITDA margins of 17.8% have held up better than we expected. Looking ahead, we see sustained industry growth, led by the console transition in Q420, with publishers increasingly recognising the resilience Keywords adds to their development processes. Following its third acquisition of the year, we see management once more focusing on M&A with net cash of €101m. Keywords’ strategy, which has delivered a five-year EPS CAGR of 42%, appears sustainable, with dividend payments to be resumed in FY21. As such, we believe that the shares remain set for continued appreciation.
Companies: Keywords Studios Plc
H1 was very challenging for NAHL due to COVID-19 but, demonstrating its resilience, the group remained profitable and free cash flow increased strongly. As a result, net debt reduced from £21.0m at December 2019 to £18.5m at June 2020. New banking covenants have been agreed and the £25m facility term extended by a year to 31 December 2022. Since the end of June the group has observed an increased demand for its services and, in August, personal injury enquiry volumes recovered to c.70% of prior year. While the potential for further lockdowns makes the short-term outlook uncertain, we continue to believe that with prudent management of short-term cash flow, NAHL can trade through the current challenges with its long-term potential undiminished.
Companies: NAHL Group Plc
Timing is everything when it comes to innovation. Too early, and even ground-breaking technology can struggle to gain traction. Too late, and the opportunity might be lost. A tricky balance. However for Rosslyn Data Tech, we think this ‘battle-hardened’, cash-rich (Est Apr’21 net funds of £6.1m) & now profitable SaaS firm is ideally placed to benefit from strong secular demand for its cutting-edge & fully integrated Big Data, AI, spend analytics, SMDM (Supplier Master Data Management) & customs/duty handling applications.
Driver Group has announced a strategic partnership with Africa’s leading claims and dispute resolution consultancy, EVRA Consulting (click here), which is headquartered in Johannesburg. The partnership combines Driver’s higher margin Diales services with EVRA’s relationships and network to bring the benefits of Expert commissions to clients across the African continent. The joint offering will give Driver access to 54 national markets across Africa. Additionally, the Group has strengthened its Middle East team, with the appointment of David Merritt, a well-known Quantum Expert with over 35 years’ experience in the construction and engineering sectors. Today’s announcement is in line with the Group’s strategy to expand its high margin Diales services, alongside diversifying into new geographies. Management guidance continues to be suspended and our forecasts therefore remain withdrawn.
Companies: Driver Group Plc
Following a number of recent contracts wins GYG’s order book now stands at record levels, which we believe should give investors confidence in current forecasts. We leave our published numbers unchanged at this juncture but believe our assumptions to be well underpinned by increasing trading momentum backed by the record order book, coupled with efficiencies and cost savings evident in the H1 margin trends.
Companies: GYG Plc
Against a backdrop of global economic turbulence driven by COVID-19, Bango’s H1 20A results confirm robust growth in End User Spend (“EUS”) and revenues, alongside record EBITDA and a solid improvement in operating cash flow. Execution in the payments business remains strong, and growth in Bango Marketplace in our view demonstrates the group’s increasing traction in data monetisation. The outlook statement is positive, and we make no changes to underlying estimates following the announcement. Overall, we continue to believe that momentum remains strong, and that the group is well placed to deliver its FY 20E targets.
Companies: Bango Plc
Frenkel Topping has acquired 6% of the share capital of NAHL and NAHL has confirmed that it has received an approach from Frenkel Topping proposing an all share combination. The Board of NAHL is considering the proposal. We move our recommendation from sell to neutral.
Open Orphan has announced that hVIVO has signed a new contract for an RSV human challenge study clinical trial with a top 3 global pharmaceutical company. The contract shows the Group's ability to convert the existing hVIVO pipeline and engage with the top customers in the industry providing great encouragement for investors in the medium term. Reiterate Buy
Companies: Open Orphan Plc
The Interims are as flagged in the July update; global lockdowns helped End User Spend (EUS) over the platform rise by 59% YoY to £743m. Encouragingly, the H1 revenue growth closely matched that rise; increasing 50% YoY, to a record £4.8m. With operational gearing in the platform, group profitability continues to rise rapidly as revenue grows; H1 adj. EBITDA of £1.1m, more than double the whole of FY 2019 earnings. The major deals delayed in FY 2019 also arrived in H1, for Platform and Bango Marketplace; notably, the purchase of a controlling stake in Audiens by Korean tech giant, NHN, assisting management focus while retaining a 40% stake in a business set to be boosted by funding and IP from its new parent. Operating activities were cash positive and capex was more than covered by an NHN investment, lifting net cash to £4.2m. This is an exciting year, with deals signed in H1 expected to help EUS reach £2bn in 2020 and leaving BGO on track to meet our FY forecasts of strong revenue growth and material profitability.
RBG Holdings had H1 revenues of £12.0m, up 17% against H1’19, of which £11.7m came from the Group’s law firm, RBL. On a LfL basis (excl. £2m of discretionary gains from litigation assets in H1’19), Group revenues were up c.46% YoY. EBITDA of £2.6m offers still-compelling margins of 22%. Transaction delays in Convex and a period of investment in LionFish held back ST performance for these higher margin divisions, yet pipelines remain healthy for Convex. Management is bullish on its ability in H2 to divest litigation assets in order to fund new investment, and in line with strategy. Continued uncertainty over timings around Convex transactions completing, and COVID headwinds, means we keep forecasts withdrawn, however suggest an intrinsic value of 90p is comfortably achievable for the shares.
Companies: RBG Holdings Plc
Dillistone is a supplier of software for the international recruitment industry. Interim results to 30 June 2020 demonstrate a profitable performance, which is highly creditable given the company's global customer base, and exposure to recruitment markets, both of which have been significantly impacted and influenced by COVID-19.
Companies: Dillistone Group Plc
Water Intelligence (WI) operates in a sizable and expanding market. The Group provides minimally invasive water leak services and is building a distribution platform to leverage its installed and growing customer base. The company is a designated Essential Service Provider during CV19 and expects to see increasing demand for its products as the Green Economy gains traction. WI's management has a proven track record of developing new revenue streams and the Group's core services are uncorrelated to either the geopolitical or economic climate. Management is selectively reacquiring franchises and converting them to corporate-operated locations. This converts indirect revenue to a direct, higher-margin income stream under the same brand, and results in improved profitability and significant earnings accretion. We believe the shares trade at a substantial discount to fair value and initiate coverage with a target price of 452p. Our scenario analysis on page 20 demonstrates that the shares could rerate at closer to 600p based on the Group's current reacquisition strategy
Companies: Water Intelligence Plc